Contribute Try STAT+ Today

The branch of the National Institutes of Health that studies alcohol abuse has not funded any new research by outside scientists specifically on the effects of alcohol advertising since its current director took over in 2014, according to a STAT analysis of grants.

At least seven such studies were funded in the decade before George Koob became director of the National Institute on Alcohol Abuse and Alcoholism in 2014. No new grants have been awarded since.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Thank you for this excellent and fair reporting. More like this please.
    I note the contrast to some STAT reporting – often regarding pharma and the opioid crisis – which feels narrative-based rather than objective.

  • Why is NIAAA Director George Koob posing for a publicity photograph wearing a white lab coat over a suit coat? Odd, no?

  • The study does not accept healthy volunteers. Participants must be at “high risk for the occurrence of a new cardiovascular disease event.” But the study also excludes individuals who receive dual antiplatelet therapy from participating. This stacks the study in favor of light drinkers faring better than abstainers in cardiovascular risk.

Comments are closed.